Price: $265.08
· 1 day: -0.05% · 5 days: +0.98% · 1 month: +0.21% · YTD: +16.01%
As of 2026-09-23 20:03 UTC.
52-week range: $190.75 – $269.39 (currently at 95% of the range).
The read
ABBV is in an uptrend, momentum firm. $265.97 is the level overhead; $262.28 the first support below.
6 of 6 technical checks lean bullish.
Price vs 50-day: above
Price vs 200-day: above
50d vs 200d avg: above
MACD: bullish
RSI momentum: 55
5-day tape: +1.0%
Trend
Uptrend · above 50-day & 200-day
Momentum
RSI 55.48 · neutral · MACD bullish
Trend strength
ADX 18.0 · weak or range
Location
+3.4% vs 50-day MA
52-week range
-0% from high · +34% from low
Volatility
ATR 5.46 · ~2.1%/day
Key levels
Level
Type
Distance
$265.97 (resistance)
52w high
0.34%
$267.22 (resistance)
swing zone
0.81%
$275.0 (resistance)
round
3.74%
$262.28 (support)
swing zone
-1.06%
$256.43 (support)
sma 50
-3.26%
$250.0 (support)
round
-5.69%
Indicators
RSI (14)
55.48
MACD
2.6166
ADX (14)
18.0
ATR (14)
5.46
50-day average
$256.43
200-day average
$230.16
Next earnings: 2026-10-29.
Latest ABBV news
ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO — ADARx Pharmaceuticals, a San Diego-based clinical stage biotechnology company, announced plans to sell 21.9 million shares at $15-$17 per share in its IPO, expecting net proceeds of approximately $318.6 million at the $1 (Morningstar, 2026-09-21)
Lilly perseveres in a bad day for drug stocks -- plus, Boeing's mixed deliveries — Pharmaceutical stocks declined significantly following Novartis's Phase 3 trial failures for its lipoprotein(a)-lowering drug, which successfully reduced Lp(a) but failed to improve cardiovascular outcomes, causing Novar (CNBC, 2026-09-08)
AbbVie Completes Acquisition of Apogee Therapeutics — AbbVie has completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion in equity value. The acquisition strengthens AbbVie's immunology pipeline with Apogee's lead (PR Newswire, 2026-09-03)